Brian Waterhouse

876 total citations
21 papers, 641 citations indexed

About

Brian Waterhouse is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Brian Waterhouse has authored 21 papers receiving a total of 641 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Brian Waterhouse's work include Diabetes Treatment and Management (5 papers), Blood Pressure and Hypertension Studies (3 papers) and Bone health and osteoporosis research (3 papers). Brian Waterhouse is often cited by papers focused on Diabetes Treatment and Management (5 papers), Blood Pressure and Hypertension Studies (3 papers) and Bone health and osteoporosis research (3 papers). Brian Waterhouse collaborates with scholars based in United States, United Kingdom and Germany. Brian Waterhouse's co-authors include Alexander R. Cobitz, Christopher M. Ryan, Mark W. J. Strachan, Martin I. Freed, B. J. Goldstein, Ninian N. Lang, Jeremy P. Langrish, Sowmya Venkatasubramanian, David E. Newby and Nicholas L. Mills and has published in prestigious journals such as PLoS ONE, Diabetes Care and Hypertension.

In The Last Decade

Brian Waterhouse

20 papers receiving 622 citations

Peers

Brian Waterhouse

EDM

PHYSI

CCM

Susan Bellman Australia

K. E. Matthys Belgium

Ametov As Russia

Keiko Fujimura Japan

Mireia Tondo Spain

Maayan Waldman Israel

Nelson Escobales Puerto Rico

Saara Merasto Finland

Bing‐Hu Li China

Susan Bellman Australia

Brian Waterhouse

159 ×0.8

EDM

241 ×1.4

261 ×1.6

PHYSI

21 ×0.2

CCM

42 ×0.4

Citations per year, relative to Brian Waterhouse Brian Waterhouse (= 1×) peers Susan Bellman

Countries citing papers authored by Brian Waterhouse

Since Specialization

Citations

This map shows the geographic impact of Brian Waterhouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Waterhouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Waterhouse more than expected).

Fields of papers citing papers by Brian Waterhouse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Waterhouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Waterhouse. The network helps show where Brian Waterhouse may publish in the future.

Co-authorship network of co-authors of Brian Waterhouse

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Waterhouse. A scholar is included among the top collaborators of Brian Waterhouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Waterhouse. Brian Waterhouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waterhouse, Brian, Alan Hartford, Saurabh Mukhopadhyay, Ryan Ferguson, & Barbara A. Hendrickson. (2021). Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation. Pharmaceutical Statistics. 21(2). 372–385. 3 indexed citations

Guttman‐Yassky, Emma, Alan D. Irvine, Jonathan I. Silverberg, et al.. (2021). 27082 Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up). Journal of the American Academy of Dermatology. 85(3). AB129–AB129.

Gordon, Kenneth B., H. Bachelez, Andrew Blauvelt, et al.. (2020). 16332 Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology. 83(6). AB176–AB176. 4 indexed citations

Mukhopadhyay, Saurabh, Brian Waterhouse, & Alan Hartford. (2018). Bayesian detection of potential risk using inference on blinded safety data. Pharmaceutical Statistics. 17(6). 823–834. 14 indexed citations

Chung, Yoon‐Sok, Dong Jin Chung, Moo-Il Kang, et al.. (2016). Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis. Yonsei Medical Journal. 57(4). 923–923. 8 indexed citations

Vachiéry, Jean‐Luc, Marius M. Hoeper, Andrew J. Peacock, et al.. (2016). Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. The Journal of Heart and Lung Transplantation. 36(4). 399–406. 9 indexed citations

Koh, Jung‐Min, Dong Jin Chung, Yoon‐Sok Chung, et al.. (2016). Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension. Yonsei Medical Journal. 57(4). 905–905. 19 indexed citations

Venkatasubramanian, Sowmya, Shruti Daga, Jeremy P. Langrish, et al.. (2016). Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus. Open Heart. 3(1). e000402–e000402. 28 indexed citations

Provencher, Steeve, et al.. (2015). Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension. PLoS ONE. 10(3). e0120657–e0120657. 9 indexed citations

10.

Pitale, Shailesh, Mathew Thomas, Gaurav Rathi, et al.. (2014). A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis. Indian Journal of Endocrinology and Metabolism. 19(1). 148–148. 11 indexed citations

11.

Venkatasubramanian, Sowmya, Shruti Daga, Jeremy P. Langrish, et al.. (2013). Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers. Journal of the American Heart Association. 2(3). e000042–e000042. 79 indexed citations

12.

Chou, Hubert S., et al.. (2007). Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obesity and Metabolism. 10(8). 626–637. 25 indexed citations

13.

Fonseca, Vivian, George L. Bakris, David S.H. Bell, et al.. (2007). Differential effect of β‐blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabetic Medicine. 24(7). 759–763. 24 indexed citations

14.

Bakris, George L., et al.. (2006). Cardiovascular Risk Factors in Hypertension: Rationale and Design of Studies to Investigate the Effects of Controlled-Release Carvedilol on Regression of Left Ventricular Hypertrophy and Lipid Profile. The American Journal of Cardiology. 98(7). 46–52. 9 indexed citations

15.

Ryan, Christopher M., et al.. (2006). Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes. Diabetes Care. 29(2). 345–351. 223 indexed citations

16.

Goldstein, Barry J., et al.. (2006). Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Current Medical Research and Opinion. 22(9). 1715–1723. 15 indexed citations

17.

Weissman, Peter N., et al.. (2005). Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Current Medical Research and Opinion. 21(12). 2029–2035. 59 indexed citations

18.

Bakris, George L., Vivian Fonseca, Richard E. Katholi, et al.. (2005). Differential Effects of β-Blockers on Albuminuria in Patients With Type 2 Diabetes. Hypertension. 46(6). 1309–1315. 65 indexed citations

19.

Ellis, B., D. N. KIRK, V. Petrow, Brian Waterhouse, & D. M. Williamson. (1960). 571. Modified steroid hormones. Part XVII. Some 6-methyl-4,6-dien-3-ones. Journal of the Chemical Society (Resumed). 2828–2828. 14 indexed citations

20.

Ellis, B., V. Petrow, & Brian Waterhouse. (1960). 523. Modified steroid hormones. Part XVI. The preparation of some 6-ethynyl-steroids. Journal of the Chemical Society (Resumed). 2596–2596. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact